Sika AG (0Z4C)
London Exchange · UK · prices in CHF · close of 19 Oct 2026
Key indicators
| Last close | CHF 180.10 |
|---|---|
| 52-week range | 118.83 – 197.40 |
| Return, 1 month / 3 months | −0.9% / +13.2% |
| Return, 1 year / 3 years | +4.4% / −19.1% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 49 |
| Volatility (1 year) | 31.3% |
| Worst drawdown (1 year) | -27.8% |
| Average daily value traded | 18.44M CHF |
| Dividend yield | 1.0% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Sika AG is a specialty chemicals company based in Switzerland that develops and produces materials for building and industry. Its construction products include concrete admixtures, mortars, sealants and adhesives used in new construction and repair work, while its industrial range covers bonding, sealing, damping and reinforcing systems for vehicle and equipment manufacturing. Customers include builders, contractors, architects and industrial manufacturers, served through local subsidiaries and distributors in many countries.
Sika AG trades under the code 0Z4C on the London Exchange in UK, with its price quoted in Swiss francs (CHF). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Sika AG (0Z4C) trades on the London Exchange in UK. It last closed at CHF 180.10 on 19 October 2026.
Its price-based Market X-Ray is 68 out of 100 (a fair price profile), ranking 694 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 4.4% and over the last three months it rose 13.2%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 80 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 12.2% | ||
| From 52-week high | -8.1% | ||
| Momentum | 71 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 13.2% | ||
| 6-month return | 18.4% | ||
| 12-month return, skipping the last month | 5.4% | ||
| Stability (higher is calmer) | 56 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 31.3% | ||
| Worst drawdown, 1 year (smaller is calmer) | -27.8% | ||
| Liquidity | 78 · Strong | Trades actively. | |
| Average daily value traded | 18.44M CHF | ||
| Zero-volume days | 0.0% | ||
| Income | 44 · Weak | Dividend is small or irregular. | |
| Dividend yield | 1.0% | ||
| Years with dividends | 5 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Liquidity: Trades actively.
Weak spots
- Income: Dividend is small or irregular.
Returns
| 1 week | +3.2% |
|---|---|
| 1 month | −0.9% |
| 3 months | +13.2% |
| 6 months | +18.4% |
| 1 year | +4.4% |
| 3 years | −19.1% |
| 5 years | – |
Signals
| 50-day / 200-day average | 185.08 / 160.45 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 4.63 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 26 Mar 2026 | CHF 1.8500 |
| 27 Mar 2025 | CHF 1.8000 |
| 28 Mar 2024 | CHF 1.6500 |
| 30 Mar 2023 | CHF 3.2000 |
| 14 Apr 2022 | CHF 2.9000 |
| 22 Apr 2021 | CHF 2.5000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.